 |
- Home
- Clinical Perspectives
- Business Perspectives
- Patient Care
- CME
- Community
- Products
- Careers
- Contact Us
Coxibs May Inhibit Effects of Low-Dose Aspirin Publish date: Dec 22, 2009  TUESDAY, Dec. 22 (HealthDay News) -- Celecoxib and other coxibs may interfere with the antiplatelet activity of low-dose
aspirin, according to a study published online Dec. 16 in the Proceedings of the National Academy of Sciences. William L. Smith, Ph.D., of the University of Michigan Medical School in Ann Arbor, and colleagues conducted in vitro experiments
using biochemical measurements and X-ray crystallography. They also conducted experiments in dogs. The researchers were surprised to find that celecoxib binds to one monomer of cyclooxygenase-1 (COX-1) and slows aspirin's
COX-1-blocking action. They also found that administration of celecoxib to dogs interfered with low-dose aspirin's ability
to inhibit arachidonic acid-induced ex vivo platelet aggregation. "It will be important to determine if celecoxib impedes the action of low-dose aspirin in humans," the authors conclude.
"A pharmacological effect of celecoxib on the action of low-dose aspirin on platelet aggregation in humans would necessitate
modifying dosing regimens to provide clinically effective COX-2 inhibition while minimizing interference with aspirin inhibition
of platelet COX-1." Copyright © 2009 ScoutNews, LLC. All rights reserved. | Featured Jobs Practice Tools Coding Counselor Simple and accurate ICD-9 code search. Start Here  Patient Education Print customized patient education handouts. Start Here  Dermatology Diagnosis Identify skin diseases by age, gender, location. Start Here  AHRQ Clinical Guidelines Objective findings on medical interventions. Start Here     |
